

# IV References List

## Alpha Lipoic Acid

1. Biewenga, G. P., Haenen, G. R., & Bast, A. (1997). The pharmacology of the antioxidant lipoic acid. *General Pharmacology: The Vascular System*, 29(3), 315-331.
2. Carbone, M., Pentenero, M., Carrozzo, M., Ippolito, A., & Gandolfo, S. (2009). Lack of efficacy of alpha-lipoic acid in burning mouth syndrome: a double-blind, randomized, placebo-controlled study. *European journal of pain*, 13(5), 492-496.
3. Carbonelli, M. G., Renzo, L. D., Bigioni, M., Daniele, N. D., De Lorenzo, A., & Fusco, M. A. (2010).  $\alpha$ -Lipoic acid supplementation: a tool for obesity therapy?. *Current pharmaceutical design*, 16(7), 840-846.
4. Choi, K. H., Park, M. S., Kim, J. T., Kim, H. S., Kim, J. H., Nam, T. S., ... & Cho, K. H. (2016). Lipoic acid use and functional outcomes after thrombolysis in patients with acute ischemic stroke and diabetes. *PloS one*, 11(9), e0163484.
- Cremer, D. R., Rabeler, R., Roberts, A., & Lynch, B. (2006). Safety evaluation of  $\alpha$ -lipoic acid (ALA). *Regulatory Toxicology and Pharmacology*, 46(1), 29-41.
5. Doggrell, S. A. (2004).  $\alpha$ -Lipoic acid, an anti-obesity agent?. *Expert opinion on investigational drugs*, 13(12), 1641-1643.
6. Farr, S. A., Price, T. O., Banks, W. A., Ercal, N., & Morley, J. E. (2012). Effect of alpha-lipoic acid on memory, oxidation, and lifespan in SAMP8 mice. *Journal of Alzheimer's Disease*, 32(2), 447-455.
7. Farr, S. A., Poon, H. F., Dogrukol-Ak, D., Drake, J., Banks, W. A., Eyerman, E., ... & Morley, J. E. (2003). The antioxidants  $\alpha$ -lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. *Journal of neurochemistry*, 84(5), 1173-1183.
8. Femiano, F., & Scully, C. (2002). Burning mouth syndrome (BMS): double blind controlled study of alpha-lipoic acid (thioctic acid) therapy. *Journal of oral pathology & medicine*, 31(5), 267-269.

9. Ford, I., Cotter, M. A., Cameron, N. E., & Greaves, M. (2001). The effects of treatment with [alpha]-lipoic acid or evening primrose oil on vascular hemostatic and lipid risk factors, blood flow, and peripheral nerve conduction in the streptozotocin-diabetic rat. *Metabolism-Clinical and Experimental*, 50(8), 868-875.
10. Gomes, M. B., & Negrato, C. A. (2014). Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases. *Diabetology & metabolic syndrome*, 6(1), 80.
11. Heinisch, B. B., Francesconi, M., Mittermayer, F., Schaller, G., Gouya, G., Wolzt, M., & Pleiner, J. (2010). Alpha-lipoic acid improves vascular endothelial function in patients with type 2 diabetes: a placebo-controlled randomized trial. *European journal of clinical investigation*, 40(2), 148-154.
12. Lateef, H., Aslam, M. N., Stevens, M. J., & Varani, J. (2005). Pretreatment of diabetic rats with lipoic acid improves healing of subsequently-induced abrasion wounds. *Archives of dermatological research*, 297(2), 75-83.
13. Li, N., Yan, W., Hu, X., Huang, Y., Wang, F., Zhang, W., ... & Sun, K. (2017). Effects of oral  $\alpha$ -lipoic acid administration on body weight in overweight or obese subjects: a crossover randomized, double-blind, placebo-controlled trial. *Clinical endocrinology*, 86(5), 680-687.
14. Marangon, K., Devaraj, S., Tirosh, O., Packer, L., & Jialal, I. (1999). Comparison of the effect of  $\alpha$ -lipoic acid and  $\alpha$ -tocopherol supplementation on measures of oxidative stress. *Free Radical Biology and Medicine*, 27(9-10), 1114-1121.
15. Marshall, A. W., Graul, R. S., Morgan, M. Y., & Sherlock, S. H. E. I. L. A. (1982). Treatment of alcohol-related liver disease with thioctic acid: a six month randomised double-blind trial. *Gut*, 23(12), 1088-1093.
16. Midaoui, A. E., Elimadi, A., Wu, L., Haddad, P. S., & De Champlain, J. (2003). Lipoic acid prevents hypertension, hyperglycemia, and the increase in heart mitochondrial superoxide production. *American journal of hypertension*, 16(3), 173-179.
17. Obrosova, I. G., Fathallah, L., Liu, E., & Nourooz-Zadeh, J. (2003). Early oxidative stress in the diabetic kidney: effect of DL- $\alpha$ -lipoic acid. *Free Radical Biology and Medicine*, 34(2), 186-195.
18. Obrosova, I. G., Fathallah, L., & Greene, D. A. (2000). Early changes in lipid peroxidation and antioxidative defense in diabetic rat retina: effect of DL- $\alpha$ -lipoic acid. *European journal of pharmacology*, 398(1), 139-146.

19. Okanović, A., Prnjavorac, B., Jusufović, E., & Sejdinović, R. (2015). Alpha-lipoic acid reduces body weight and regulates triglycerides in obese patients with diabetes mellitus. *Medicinski glasnik*, 12(2).
20. Packer, L., Witt, E. H., & Tritschler, H. J. (1995). Alpha-lipoic acid as a biological antioxidant. *Free radical biology and medicine*, 19(2), 227-250.
21. Rodriguez, M. C., MacDonald, J. R., Mahoney, D. J., Parise, G., Beal, M. F., & Tarnopolsky, M. A. (2007). Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. *Muscle & nerve*, 35(2), 235-242.
22. Shay, K. P., Moreau, R. F., Smith, E. J., Smith, A. R., & Hagen, T. M. (2009). Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. *Biochimica et Biophysica Acta (BBA)-General Subjects*, 1790(10), 1149-1160.
23. Tabassum, H., Parvez, S., Pasha, S. T., Banerjee, B. D., & Raisuddin, S. (2010). Protective effect of lipoic acid against methotrexate-induced oxidative stress in liver mitochondria. *Food and chemical toxicology*, 48(7), 1973-1979.
24. Teichert, J., Tuemmers, T., Achenbach, H., Preiss, C., Hermann, R., Ruus, P., & Preiss, R. (2005). Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney damage and end-stage renal disease. *The Journal of Clinical Pharmacology*, 45(3), 313-328.
25. Teichert, J., Kern, J., Tritschler, H. J., Ulrich, H., & Preiss, R. (1998). Investigations on the pharmacokinetics of alpha-lipoic acid in healthy volunteers. *International journal of clinical pharmacology and therapeutics*, 36(12), 625-628.
26. Vasdev, S., Ford, C. A., Parai, S., Longerich, L., & Gadag, V. (2000). Dietary  $\alpha$ -lipoic acid supplementation lowers blood pressure in spontaneously hypertensive rats. *Journal of hypertension*, 18(5), 567-573.
27. Whitworth, J. A. (2013). The effect of alpha-lipoic acid on mitochondrial superoxide and glucocorticoid-induced hypertension. *Oxidative medicine and cellular longevity*, 2013.
28. Zembron-Lacny, A., Slowinska-Lisowska, M., Szygula, Z., Witkowski, K., Stefaniak, T., & Dziubek, W. (2009). Assessment of the antioxidant effectiveness of alpha-lipoic acid in healthy men exposed to muscle-damaging exercise. *J Physiol Pharmacol*, 60(2), 139-43.
29. Ziegler, D., & Gries, F. A. (1997).  $\alpha$ -Lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. *Diabetes*, 46(Supplement 2), S62-S66.

# Arginine

1. Ellinger, S. (2014). Micronutrients, arginine, and glutamine: does supplementation provide an efficient tool for prevention and treatment of different kinds of wounds?. *Advances in wound care*, 3(11), 691-707.
2. Neyens, J. C., Cereda, E., Rozsos, I., Molnár, A., & Rondas, A. (2017). Effects of an arginine-enriched oral nutritional supplement on the healing of chronic wounds in non-malnourished patients; a multicenter case series from the Netherlands and Hungary. *J Gerontol Geriatr Res*, 6(420), 2.
3. Shi, H. P., Most, D., Efron, D. T., Witte, M. B., & Barbul, A. (2003). Supplemental L-arginine enhances wound healing in diabetic rats. *Wound repair and regeneration*, 11(3), 198-203.
4. Stechmiller, J. K., Childress, B., & Cowan, L. (2005). Arginine supplementation and wound healing. *Nutrition in Clinical Practice*, 20(1), 52-61.

# Glutathione

1. Godic, A., Poljšak, B., Adamic, M., & Dahmane, R. (2014). The role of antioxidants in skin cancer prevention and treatment. *Oxidative medicine and cellular longevity*, 2014.
2. Hauser, R. A., Lyons, K. E., McClain, T., Carter, S., & Perlmutter, D. (2009). Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. *Movement Disorders*, 24(7), 979-983.
3. Sonthalia, S., Daulatabad, D., & Sarkar, R. (2016). Glutathione as a skin whitening agent: Facts, myths, evidence and controversies. *Indian Journal of Dermatology, Venereology, and Leprology*, 82(3), 262.
4. Sonthalia, S., & Sarkar, R. (2017). Glutathione for skin lightning: an update. *Pigment International*, 4(1), 3.
5. Sonthalia, S., Jha, A. K., Lallas, A., Jain, G., & Jakhar, D. (2018). Glutathione for skin lightening: a regnant myth or evidence-based verity?. *Dermatology practical & conceptual*, 8(1), 15.
6. Weschawalit, S., Thongthip, S., Phutrakool, P., & Asawanonda, P. (2017). Glutathione and its antiaging and antimelanogenic effects. *Clinical, cosmetic and investigational dermatology*, 10, 147.
7. Witschi, A., Reddy, S., Stofer, B., & Lauterburg, B. H. (1992). The systemic availability of oral glutathione. *European journal of clinical pharmacology*, 43(6), 667-669.

# NAD

1. Belenky, P., Bogan, K. L., & Brenner, C. (2007). NAD<sup>+</sup> metabolism in health and disease. *Trends in biochemical sciences*, 32(1), 12-19.
- Birkmayer, G. (1998). NADH the energizing coenzyme. Connecticut: Keats.
2. Birkmayer, G. D. (1995). Nicotinamide Adenine Dinucleotide (NADH)-a new therapeutic approach: Preliminary results with cancer patients and patients with dementia of the Alzheimer type. *Journal of tumor marker oncology*, 10, 71-71.
3. Birkmayer, G. D. (1999). The NADH reaction: European study documents effects of NADH on Alzheimer patients. *Adv in Neurol*, 53.
- Birkmayer, W., & Birkmayer, G. J. (1989). Nicotinamidadeninucleotide (NADH): the new approach in the therapy of Parkinson's disease. *Annals of Clinical & Laboratory Science*, 19(1), 38-43.
4. Braidy, N., Berg, J., Clement, J., Khorshidi, F., Poljak, A., Jayasena, T., ... & Sachdev, P. (2018). Role of nicotinamide adenine dinucleotide and related precursors as therapeutic targets for age-related degenerative diseases: rationale, biochemistry, pharmacokinetics, and outcomes. *Antioxidants & redox signaling*, 30(2), 251-294.
5. Carson, D.A., Seto, S., Watson, D.B. & Carrera, C.J. (1986). DNA strand breaks, NAD metabolism, and programmed cell death. *Exp Cell Res* 1986 Jun;164(2):273-81
- Chung, K.T. (1982). An association of carcinogenesis and decrease of cellular NAD concentration. *Chung Hua Min Kuo Wei Sheng Wu Chi Mien I Hsueh Tsa Chih* 1982 Nov;15(4):309-18
6. Cleary, J. P. (1986). The NAD deficiency diseases. *J Orthomol Med*, 1(3), 149-157.
7. Demarin, V., Podobnik, S. S., Storga-Tomic, D., & Kay, G. (2004). Treatment of Alzheimer's disease with stabilized oral nicotinamide adenine dinucleotide: a randomized, double-blind study. *Drugs under experimental and clinical research*, 30(1), 27-33.
8. Forsyth, L.M., Preuss, H.G., MacDowell, A.L., Chiazze, L., Birkmayer, G.D. & Bellanti, J.A.(1999). Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome. *Annals of Allergy, Asthma and Immunology*, 82(2), 185-191.
9. Fukuwatari T, Shibata K, Ishihara K, Fushiki T, Sugimoto E. Elevation of blood NAD level after moderate exercise in young women and mice. *J Nutr Sci Vitaminol (Tokyo)*. 2001 Apr;47(2):177-9.)
10. Gariani, K., Menzies, K. J., Ryu, D., Wegner, C. J., Wang, X., Ropelle, E. R., ... & Kim, B. (2016). Eliciting the mitochondrial unfolded protein response by nicotinamide adenine dinucleotide repletion reverses fatty liver disease in mice. *Hepatology*, 63(4), 1190-1204.
11. Humiston, John. Pharmacy Compounding Committee Review: Nicotinamide Adenine Dinucleotide (NAD<sup>+</sup>). May 2017, <https://www.fda.gov/media/113016/download> . PowerPoint Presentation.
12. Jacobson, E.L., Shieh, W.M. & Huang, A.C. (1999). Mapping the role of NAD metabolism in prevention and treatment of carcinogenesis. *Mol Cell Biochem* 1999 Mar;193(1-2):69-74
13. Nadlinger K, Westerthaler W, Storga-Tomic D, Birkmayer JG. Extracellular metabolism of NADH by blood cells correlates with intracellular ATP levels. *Biochim Biophys Acta*. 2002

Nov 14;1573(2):177-82.

14. Rex, A., & Fink, H. (2008). Pharmacokinetic aspects of reduced nicotinamide adenine dinucleotide (NADH) in rats. *Front Biosci*, 13, 3735-3741.

## Neuropathy Diabetic

1. Ametov, A. S., Barinov, A., Dyck, P. J., Hermann, R., Kozlova, N., Litchy, W. J., ... & Reljanovic, M. (2003). The sensory symptoms of diabetic polyneuropathy are improved with [alpha]-lipoic acid: the SYDNEY trial. (Original Article: Emerging Treatments and Technologies). *Diabetes Care*, 26(3), 770-777.

2. Gu, X. M., Zhang, S. S., Wu, J. C., Tang, Z. Y., Lu, Z. Q., Li, H., ... & Ning, G. (2010). Efficacy and safety of high-dose  $\alpha$ -lipoic acid in the treatment of diabetic polyneuropathy. *Zhonghua Yi Xue Za Zhi*, 90(35), 2473-2476.

3. Han, T., Bai, J., Liu, W., & Hu, Y. (2012). THERAPY OF ENDOCRINE DISEASE: A systematic review and meta-analysis of  $\alpha$ -lipoic acid in the treatment of diabetic peripheral neuropathy. *European journal of endocrinology*, 167(4), 465-471.

4. Jin, H. Y., Joung, S. J., Park, J. H., Baek, H. S., & Park, T. S. (2007). The effect of  $\alpha$ -lipoic acid on symptoms and skin blood flow in diabetic neuropathy. *Diabetic Medicine*, 24(9), 1034-1038.

5. Mijnhout, G. S., Alkhalaf, A., Kleefstra, N., & Bilo, H. J. (2010). Alpha lipoic acid: a new treatment for neuropathic pain in patients with diabetes. *Neth J Med*, 68(4), 158-62.

6. Mijnhout, G. S., Kollen, B. J., Alkhalaf, A., Kleefstra, N., & Bilo, H. J. (2012). Alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials. *International journal of endocrinology*, 2012.

7. Reljanovic, M., Reichel, G., Rett, K., Lobisch, M., Schuette, K., Möller, W., ... & Mehnert, H. (1999). Treatment of diabetic polyneuropathy with the antioxidant thioctic acid ( $\alpha$ -lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). *Free radical research*, 31(3), 171-179.

8. Ziegler, D., Ametov, A., Barinov, A., Dyck, P. J., Gurieva, I., Low, P. A., ... & Maus, J. (2006). Oral treatment with  $\alpha$ -lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. *Diabetes care*, 29(11), 2365-2370.

9. Ziegler, D., & Gries, F. A. (1997).  $\alpha$ -Lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. *Diabetes*, 46(Supplement 2), S62-S66.

10. Ziegler, D., Hanefeld, M., Ruhnau, K. J., Hasche, H., Lobisch, M., Schütte, K. L. E. M. E. N. S., ... & Malessa, R. (1999). Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. *Alpha-Lipoic Acid in Diabetic Neuropathy*. *Diabetes care*, 22(8), 1296-1301.

11. Ziegler, D., Low, P. A., Litchy, W. J., Boulton, A. J., Vinik, A. I., Freeman, R., ... & Schütte, K. (2011). Efficacy and safety of antioxidant treatment with  $\alpha$ -lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. *Diabetes care*, 34(9), 2054-2060.

12. Ziegler, D., Nowak, H., Kempler, P., Vargha, P., & Low, P. A. (2004). Treatment of symptomatic diabetic polyneuropathy with the antioxidant  $\alpha$ -lipoic acid: a meta-analysis. *Diabetic Medicine*, 21(2), 114-121.

## Neuropathy

1. Gado, A. M., El-Mashad, W., & El-Mashad, N. Role of Alpha Lipoic Acid in Prevention of Oxaliplatin Neurological Toxicity.

2. Gedlicka, C., Scheithauer, W., Schull, B., & Kornek, G. V. (2002). Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. *Journal of clinical oncology*, 20(15), 3359-3361.

3. Melli, G., Taiana, M., Camozzi, F., Triolo, D., Podini, P., Quattrini, A., ... & Lauria, G. (2008). Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy. *Experimental neurology*, 214(2), 276-284.

## Oxidative Stress

1. Farr, S. A., Price, T. O., Banks, W. A., Ercal, N., & Morley, J. E. (2012). Effect of alpha-lipoic acid on memory, oxidation, and lifespan in SAMP8 mice. *Journal of Alzheimer's Disease*, 32(2), 447-455.

2. Farr, S. A., Poon, H. F., Dogrukol-Ak, D., Drake, J., Banks, W. A., Eyerman, E., ... & Morley, J. E. (2003). The antioxidants  $\alpha$ -lipoic acid and N-acetylcysteine reverse memory impairment and

brain oxidative stress in aged SAMP8 mice. *Journal of neurochemistry*, 84(5), 1173-1183.

3. Marangon, K., Devaraj, S., Tirosh, O., Packer, L., & Jialal, I. (1999). Comparison of the effect of  $\alpha$ -lipoic acid and  $\alpha$ -tocopherol supplementation on measures of oxidative stress. *Free Radical Biology and Medicine*, 27(9-10), 1114-1121.

4. Obrosova, I. G., Fathallah, L., & Greene, D. A. (2000). Early changes in lipid peroxidation and antioxidative defense in diabetic rat retina: effect of DL- $\alpha$ -lipoic acid. *European journal of pharmacology*, 398(1), 139-146. (edited)

## SILVER

1. Apsley, J., Holtorf, K., Gordon, E., Anderson, W., & Buttar, R. (2006). Nanotechnology's latest oncolytic agent: silver, cancer, & infection associations. *Townsend Letter: The Examiner of Alternative Medicine*, (274), 95-99.

2. Li, P., Li, J., Wu, C., Wu, Q., & Li, J. (2005). Synergistic antibacterial effects of  $\beta$ -lactam antibiotic combined with silver nanoparticles. *Nanotechnology*, 16(9), 1912.

3. Nadworny, P. L., Wang, J., Tredget, E. E., & Burrell, R. E. (2010). Anti-inflammatory activity of nanocrystalline silver-derived solutions in porcine contact dermatitis. *Journal of inflammation*, 7(1), 13

## Vitamin C and Cancer

1. Gaby, A. (2011). *Nutritional medicine* (Vol. 265). Concord: Fritz Perlberg Publishing.

2. National Cancer Institute. July 2019. High-Dose Vitamin C (PDQ) - Health Professional Version. <https://www.cancer.gov/about-cancer/treatment/cam/hp/vitamin-c-pdq>

3. Xia, J., Xu, H., Zhang, X., Allamargot, C., Coleman, K. L., Nessler, R., ... & Zhan, F. (2017). Multiple myeloma tumor cells are selectively killed by pharmacologically-dosed ascorbic acid. *EBioMedicine*, 18, 41-49.

### Human Studies

4. Cameron E, Campbell A: The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. *Chem Biol Interact* 9 (4): 285-315, 1974. [PUBMED Abstract]

5. Cameron E, Campbell A, Jack T: The orthomolecular treatment of cancer. III. Reticulum cell sarcoma: double complete regression induced by high-dose ascorbic acid therapy. *Chem Biol Interact* 11 (5): 387-93, 1975. [PUBMED Abstract]
6. Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. *Proc Natl Acad Sci U S A* 73 (10): 3685-9, 1976. [PUBMED Abstract]
7. Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. *Proc Natl Acad Sci U S A* 75 (9): 4538-42, 1978. [PUBMED Abstract]
8. Creagan ET, Moertel CG, O'Fallon JR, et al.: Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. *N Engl J Med* 301 (13): 687-90, 1979. [PUBMED Abstract]
9. Moertel CG, Fleming TR, Creagan ET, et al.: High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. *N Engl J Med* 312 (3): 137-41, 1985. [PUBMED Abstract]
10. Padayatty SJ, Riordan HD, Hewitt SM, et al.: Intravenously administered vitamin C as cancer therapy: three cases. *CMAJ* 174 (7): 937-42, 2006. [PUBMED Abstract]
11. Vollbracht C, Schneider B, Leendert V, et al.: Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany. *In Vivo* 25 (6): 983-90, 2011 Nov-Dec. [PUBMED Abstract]
12. Yeom CH, Jung GC, Song KJ: Changes of terminal cancer patients' health-related quality of life after high dose vitamin C administration. *J Korean Med Sci* 22 (1): 7-11, 2007. [PUBMED Abstract]
13. Padayatty SJ, Sun H, Wang Y, et al.: Vitamin C pharmacokinetics: implications for oral and intravenous use. *Ann Intern Med* 140 (7): 533-7, 2004. [PUBMED Abstract]
14. Hoffer LJ, Levine M, Assouline S, et al.: Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. *Ann Oncol* 19 (11): 1969-74, 2008. [PUBMED Abstract]
15. Monti DA, Mitchell E, Bazzan AJ, et al.: Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. *PLoS One* 7 (1): e29794, 2012. [PUBMED Abstract]

16. Welsh JL, Wagner BA, van't Erve TJ, et al.: Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. *Cancer Chemother Pharmacol* 71 (3): 765-75, 2013. [PUBMED Abstract]
17. Ma Y, Chapman J, Levine M, et al.: High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. *Sci Transl Med* 6 (222): 222ra18, 2014. [PUBMED Abstract]
18. Abou-Jawde RM, Reed J, Kelly M, et al.: Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial. *Med Oncol* 23 (2): 263-72, 2006. [PUBMED Abstract]
19. Berenson JR, Matous J, Swift RA, et al.: A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. *Clin Cancer Res* 13 (6): 1762-8, 2007. [PUBMED Abstract]
20. Qazilbash MH, Saliba RM, Nieto Y, et al.: Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. *Biol Blood Marrow Transplant* 14 (12): 1401-7, 2008. [PUBMED Abstract]
21. Berenson JR, Boccia R, Siegel D, et al.: Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. *Br J Haematol* 135 (2): 174-83, 2006. [PUBMED Abstract]
22. Subbarayan PR, Lima M, Ardalan B: Arsenic trioxide/ascorbic acid therapy in patients with refractory metastatic colorectal carcinoma: a clinical experience. *Acta Oncol* 46 (4): 557-61, 2007. [PUBMED Abstract]
23. Bael TE, Peterson BL, Gollob JA: Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases. *Melanoma Res* 18 (2): 147-51, 2008. [PUBMED Abstract]
24. Schoenfeld JD, Sibenaller ZA, Mapuskar KA, et al.: O<sub>2</sub><sup>-</sup> and H<sub>2</sub>O<sub>2</sub>-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. *Cancer Cell* 32 (2): 268, 2017. [PUBMED Abstract]

## **Synergistic and Inhibitory Effects of Vitamin C**

25. Padayatty SJ, Sun H, Wang Y, et al.: Vitamin C pharmacokinetics: implications for oral and intravenous use. *Ann Intern Med* 140 (7): 533-7, 2004. [PUBMED Abstract]
26. Hoffer LJ, Levine M, Assouline S, et al.: Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. *Ann Oncol* 19 (11): 1969-74, 2008. [PUBMED Abstract]
27. Chen Q, Espey MG, Sun AY, et al.: Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. *Proc Natl Acad Sci U S A* 105 (32): 11105-9, 2008. [PUBMED Abstract]
28. Monti DA, Mitchell E, Bazzan AJ, et al.: Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. *PLoS One* 7 (1): e29794, 2012. [PUBMED Abstract]
29. Abou-Jawde RM, Reed J, Kelly M, et al.: Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial. *Med Oncol* 23 (2): 263-72, 2006. [PUBMED Abstract]
30. Berenson JR, Matous J, Swift RA, et al.: A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. *Clin Cancer Res* 13 (6): 1762-8, 2007. [PUBMED Abstract]
31. Qazilbash MH, Saliba RM, Nieto Y, et al.: Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. *Biol Blood Marrow Transplant* 14 (12): 1401-7, 2008. [PUBMED Abstract]
32. Ma Y, Chapman J, Levine M, et al.: High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. *Sci Transl Med* 6 (222): 222ra18, 2014. [PUBMED Abstract]
33. Padayatty SJ, Sun AY, Chen Q, et al.: Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. *PLoS One* 5 (7): e11414, 2010. [PUBMED Abstract]
34. Campbell GD, Steinberg MH, Bower JD: Letter: Ascorbic acid-induced hemolysis in G-6-PD deficiency. *Ann Intern Med* 82 (6): 810, 1975. [PUBMED Abstract]
35. Mehta JB, Singhal SB, Mehta BC: Ascorbic-acid-induced haemolysis in G-6-PD deficiency. *Lancet* 336 (8720): 944, 1990. [PUBMED Abstract]
36. Rees DC, Kelsey H, Richards JD: Acute haemolysis induced by high dose ascorbic acid in glucose-6-phosphate dehydrogenase deficiency. *BMJ* 306 (6881): 841-2, 1993. [PUBMED Abstract]

37. Barton JC, McDonnell SM, Adams PC, et al.: Management of hemochromatosis. Hemochromatosis Management Working Group. *Ann Intern Med* 129 (11): 932-9, 1998. [PUBMED Abstract]
38. Welsh JL, Wagner BA, van't Erve TJ, et al.: Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. *Cancer Chemother Pharmacol* 71 (3): 765-75, 2013. [PUBMED Abstract]
39. Zou W, Yue P, Lin N, et al.: Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells. *Clin Cancer Res* 12 (1): 273-80, 2006. [PUBMED Abstract]
40. Llobet D, Eritja N, Encinas M, et al.: Antioxidants block proteasome inhibitor function in endometrial carcinoma cells. *Anticancer Drugs* 19 (2): 115-24, 2008. [PUBMED Abstract]
41. Perrone G, Hideshima T, Ikeda H, et al.: Ascorbic acid inhibits antitumor activity of bortezomib in vivo. *Leukemia* 23 (9): 1679-86, 2009. [PUBMED Abstract]
42. Bannerman B, Xu L, Jones M, et al.: Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea. *Cancer Chemother Pharmacol* 68 (5): 1145-54, 2011. [PUBMED Abstract]
43. Heaney ML, Gardner JR, Karasavvas N, et al.: Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. *Cancer Res* 68 (19): 8031-8, 2008. [PUBMED Abstract]